Literature DB >> 28550116

Myeloid-derived cells in prostate cancer progression: phenotype and prospective therapies.

Zoila Lopez-Bujanda1,2, Charles G Drake3.   

Abstract

Prostate cancer is the second most common cause of cancer mortality in men in the United States. As is the case for other tumor types, accumulating evidence suggests an important role for myeloid-derived cells in the promotion and progression of prostate cancer. Here, we briefly describe myeloid-derived cells that interact with tumor cells and what is known about their immune suppressive function. We next discuss new evidence for tumor cell-mediated myeloid infiltration via the PI3K/PTEN/AKT signaling pathway and an alternative mechanism for immune evasion that may be regulated by an endoplasmic reticulum stress response. Finally, we discuss several interventions that target myeloid-derived cells to treat prostate cancer. © Society for Leukocyte Biology.

Entities:  

Keywords:  castration-resistant prostate cancer; immune infiltration; immunosuppression; myeloid-derived suppressor cell; tumor microenvironment; tumor-associated macrophage

Mesh:

Year:  2017        PMID: 28550116      PMCID: PMC6608078          DOI: 10.1189/jlb.5VMR1116-491RR

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  28 in total

Review 1.  Potentiating prostate cancer immunotherapy with oncolytic viruses.

Authors:  Patrick Lee; Shashi Gujar
Journal:  Nat Rev Urol       Date:  2018-02-13       Impact factor: 14.432

Review 2.  Targeting the Tumor Microenvironment with Immunotherapy for Genitourinary Malignancies.

Authors:  Ariel E Marciscano; Ravi A Madan
Journal:  Curr Treat Options Oncol       Date:  2018-03-08

3.  Castration-mediated IL-8 promotes myeloid infiltration and prostate cancer progression.

Authors:  Zoila A Lopez-Bujanda; Michael C Haffner; Matthew G Chaimowitz; Nivedita Chowdhury; Nicholas J Venturini; Radhika A Patel; Aleksandar Obradovic; Corey S Hansen; Joanna Jacków; Janielle P Maynard; Karen S Sfanos; Cory Abate-Shen; Charles J Bieberich; Paula J Hurley; Mark J Selby; Alan J Korman; Angela M Christiano; Angelo M De Marzo; Charles G Drake
Journal:  Nat Cancer       Date:  2021-07-19

Review 4.  Novel Redirected T-Cell Immunotherapies for Advanced Prostate Cancer.

Authors:  Tanya B Dorff; Vivek Narayan; Stephen J Forman; Peter D Zang; Joseph A Fraietta; Carl H June; Naomi B Haas; Saul J Priceman
Journal:  Clin Cancer Res       Date:  2022-02-15       Impact factor: 13.801

5.  Tumor-infiltrating mesenchymal stem cells: Drivers of the immunosuppressive tumor microenvironment in prostate cancer?

Authors:  Timothy E Krueger; Daniel L J Thorek; Alan K Meeker; John T Isaacs; W Nathaniel Brennen
Journal:  Prostate       Date:  2018-11-28       Impact factor: 4.104

6.  STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers.

Authors:  Dayson Moreira; Tomasz Adamus; Xingli Zhao; Yu-Lin Su; Zhuoran Zhang; Seok Voon White; Piotr Swiderski; Xin Lu; Ronald A DePinho; Sumanta K Pal; Marcin Kortylewski
Journal:  Clin Cancer Res       Date:  2018-10-18       Impact factor: 12.531

7.  Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy.

Authors:  Jessica E Hawley; Samuel Pan; William D Figg; Zoila A Lopez-Bujanda; Jonathan D Strope; David H Aggen; Matthew C Dallos; Emerson A Lim; Mark N Stein; Jianhua Hu; Charles G Drake
Journal:  Prostate       Date:  2020-01-03       Impact factor: 4.104

Review 8.  Immunotherapy for Prostate Cancer.

Authors:  Nicholas J Venturini; Charles G Drake
Journal:  Cold Spring Harb Perspect Med       Date:  2019-05-01       Impact factor: 6.915

Review 9.  Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?

Authors:  Vicenç Ruiz de Porras; Juan Carlos Pardo; Lucia Notario; Olatz Etxaniz; Albert Font
Journal:  Int J Mol Sci       Date:  2021-04-29       Impact factor: 5.923

10.  TGM4: an immunogenic prostate-restricted antigen.

Authors:  Zoila A Lopez-Bujanda; Aleksandar Obradovic; Thomas R Nirschl; Laura Crowley; Rodney Macedo; Alexandros Papachristodoulou; Timothy O'Donnell; Uri Laserson; Jelani C Zarif; Ran Reshef; Tiezheng Yuan; Mithil K Soni; Emmanuel S Antonarakis; Michael C Haffner; H Benjamin Larman; Michael M Shen; Pawel Muranski; Charles G Drake
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.